Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

th chronic

lymphocytic leukemia is expected to be started in the United States by

Micromet's collaboration partner MedImmune. In addition, at the

conference of the American Society of Hematology (ASH) in December 2008,

Micromet anticipates that it will provide an update on the clinical

data of the ongoing clinical trials with MT103.

-- Micromet expects to initiate dosing of patients in a phase 1 clinical

trial of MT110 in patients with solid tumors in the first half of 2008.

-- Micromet is currently developing the study design for a clinical trial

to evaluate adecatumumab (MT201) in an adjuvant setting and plans to

initiate this clinical trial in the second half of 2008. In addition,

data of the ongoing phase 1b combination trial with docetaxel are

expected to be presented in the second half of 2008.

-- Micromet expects to initiate IND-enabling studies with MT203 as part of

its collaboration with Nycomed.

Conference Call and Audio Webcast Today, March 13, 2007, at 9:00am Eastern Time

To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical t
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Research and ... Electronics Market by Material, by Application, Geography - Global ... their offering. Organic electronics, also called ... of material science which deals with small conductive molecules ... because small molecules and polymers are carbon based, made ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... -- NextCODE Health, which enables clinicians and researchers to use ... announced the launch of its new genomic data analysis and ... Society of Human Genetics (ASHG) annual meeting in ... apply for free beta access, visit www.nextcode.com . A ... viewed here . The Exchange: ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Sept. 22, 2011 PrimeraDx today announced that Albert Luderer ... President and CEO Matthew McManus commented:  "We are excited ...  We have just launched the ICE Plex System, which ... high multiplex, multi-modal qPCR, and Al brings many years of ...
... A team of researchers from Roche ( SIX: RO, ... and Early Development and Roche NimbleGen, reported inGenome Research (1) ... the cynomolgus monkey ( Macaca fascicularis ) and developed a ... in preclinical drug safety research. The cynomolgus macaque ...
... a rain, the cupped leaf of a pitcher plant becomes ... ants, spiders, and even little frogs. One by one, they ... a group of applied scientists at Harvard have created a ... blood and oil, and does so even under harsh conditions ...
Cached Biology Technology:PrimeraDx Appoints Albert A. Luderer to its Board of Directors 2Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment 2Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment 3Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment 4Slippery slope:Researchers take advice from a carnivorous plant 2Slippery slope:Researchers take advice from a carnivorous plant 3
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... linking prostate cancer to an obscure retrovirus derived from ... a forensic analysis of tissue samples and lab experiments ... confirmed. The connection, which scientists have questioned repeatedly ... than six years ago, when the telltale signature of ...
... wildlife ecologist Aldo Leopold was a meticulous taker of field ... at his Sauk County shack in Depression-era Wisconsin, Leopold routinely ... the first pre-dawn calls of the indigo bunting or robin, ... he heard, when he heard them, and details such as ...
... Md. (September 18, 2012)Propelled by rapid growth in the ... the American Physiological Society (APS; www.the-APS.org ), announced ... its editorial policy. The journal will continue to ... will dramatically increase the scope of papers accepted to ...
Cached Biology News:New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause 2New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause 3New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause 4Aldo Leopold's field notes score a lost 'soundscape' 2Aldo Leopold's field notes score a lost 'soundscape' 3Physiological Genomics journal announces a major restructuring 2Physiological Genomics journal announces a major restructuring 3Physiological Genomics journal announces a major restructuring 4Physiological Genomics journal announces a major restructuring 5
HistoScan AP Universal Goat Kit...
...
Used in May-Grunwald Giemsa stain....
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
Biology Products: